Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TransMedics Group ( (TMDX) ) just unveiled an announcement.
On May 22, 2025, TransMedics Group, Inc. held its 2025 Annual Meeting of Shareholders, where several key proposals were voted on. The shareholders elected eight directors to serve on the Board until the 2026 Annual Meeting, approved the compensation for the company’s executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.
The most recent analyst rating on (TMDX) stock is a Buy with a $109.00 price target. To see the full list of analyst forecasts on TransMedics Group stock, see the TMDX Stock Forecast page.
Spark’s Take on TMDX Stock
According to Spark, TipRanks’ AI Analyst, TMDX is a Outperform.
TransMedics Group’s overall score reflects strong revenue growth and operational efficiency, offset by high debt levels and cash flow challenges. The stock’s bullish technical indicators are promising, but the high valuation presents a risk. Positive earnings call guidance and strategic initiatives further support the stock’s outlook.
To see Spark’s full report on TMDX stock, click here.
More about TransMedics Group
TransMedics Group, Inc. operates in the medical technology industry, focusing on the development and commercialization of organ transplant systems. The company is known for its Organ Care System (OCS) technology, which is designed to improve organ preservation and transportation, thereby enhancing the outcomes of transplant procedures.
Average Trading Volume: 1,191,190
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.17B
For a thorough assessment of TMDX stock, go to TipRanks’ Stock Analysis page.